New back­ers Sofinno­va and Scopia bring Y-mAb's round to $80M for an­ti-can­cer drugs

Two promi­nent in­vestors have squeezed in­to last month’s fi­nanc­ing round for Y-mAbs, a biotech launched by Gen­mab vet­er­ans, bring­ing an ad­di­tion­al $30 mil­lion to the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER